Expert Interview
Exploring the current treatment landscape and the future direction of available NASH specific drugs with the introduction of GLP-1 agonists
Ticker(s): MDGL, TERN, ETNB, VKTXInstitution: Western University
- Associate Professor of Medicine at the Division of Gastroenterology, and Department of Epidemiology and Biostatistics at Western University
- Transplant hepatologist and clinical researcher with interest in clinical/translational research and epidemiology in alcohol-related disease and NAFLD
- Published more than 150 peer-reviewed papers, co-authored several book chapters and delivered lectures on liver-related topics at national and international meetings
Roughly how many patients do you currently manage with NASH?
Added By: dami_adminCan we discuss the NASH landscape and this drug from TERN-501 had phase two data in August?
How do you see the impact of GLP-1s on the NASH market, especially with the introduction of weight loss drugs like Wegovys and Ozempics?
Do you think the introduction of bariatric surgeries didn't make much of an impact on obesity because it wasn't as widely adopted?
Do GLP-1s have a better chance to change the curve of obesity rates in the country compared to surgeries?
When discussing combination therapies, are you mainly referring to patients who have already developed NASH?
Looking 10 years from now, if reimbursement for GLP-1s gets sorted, what do you think the impact on NASH will be? Will we have more, the same, or fewer NASH patients?
Do you think the introduction of GLP-1s will reduce the addressable patient population for NASH-specific medications?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
